Evidence-Based Approaches to Managing Hypoparathyroidism

San Francisco, CA US

Target Audience

This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, and healthcare professionals who treat patients with bone disorders.

Learning Objectives

Upon completion of this educational activity, learners will be better able to:

  • Describe the pathophysiology and differential diagnosis of hypoparathyroidism
  • Appreciate the complications of chronic hypoparathyroidism and its treatment
  • Understand the current clinical management of hypoparathyroidism and how to minimize sequelae
  • Understand the mechanism of emerging therapies in the management of hypoparathyroidism and their application
  • Summarize current clinical studies on the safety and efficacy of human parathyroid hormone treatment in hypoparathyroidism

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Medical Knowledge
Practice-based Learning and Improvement
Systems-based Practice
Topic Area: 
Bone and Calciotropic Hormones
General Endocrinology
Thyroid/HPT Axis
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation
Course opens: 
Course expires: 
Hilton San Francisco Union Square
333 O'Farrell Street
San Francisco, CA 94102
United States

Dolores M Shoback, MD – Program Director
Professor of Medicine
University of California, San Francisco
San Francisco VA Medical Center
San Francisco, California

Michael A Levine, MD
Chief, Division of Endocrinology and Diabetes
The Children’s Hospital of Philadelphia
Philadelphia, Pennsylvania

Michael R McClung, MD
Director, Oregon Osteoporosis Center
Portland, Oregon

Michael Mannstadt, MD
Assistant Professor in Medicine
Harvard Medical School
Massachusetts General Hospital
Boston, Massachusetts

Disclosure Policy

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

Michael Mannstadt, MD: Advisory Board Member, NPS Pharmaceuticals, Inc.

Michael A Levine, MD, FAAP, FACP: Advisory Board Member and Consultant, NPS Pharmaceuticals

Dolores M Shoback, MD: Consultant, NPS Pharmaceuticals, Inc.

The following faculty reported no relevant financial relationships:  Michael R McClung, MD

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:

E. Michael Lewiecki, MDConsultant, Amgen, Eli Lilly, Merck, Radius Health, AgNovos Healthcare, Theranova; Research Grant Support, Amgen, Eli Lilly, Merck;

The following SPC Committee members reported relevant financial relationships:

Sarah Berga, MDAdvisory Board Member, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.

Paresh Dandona, MD, PhD, FRCPConsultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk

Irl B Hirsch, MD: Consultant, Abbott Laboratories, Becton Dickinson, Roche Diagnostics; Grant Support, Halozyme, Sanofi

Anton Luger, MD: Advisory Board Member, Investigator and Speaker, Novo Nordisk; Advisory Board Member and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche

Guillermo E Umpierrez, MD, CDEAdvisory Board and Consultant, Abbott, Boehringer Ingelheim, Merck, Novo Nordisk, Regeneron, Sanofi; Research Grant Support, Boehringer Ingelheim, Merck & Co., Novo Nordisk, Regeneron

Andrea L Utz, MD, PhDInvestigator, Corcept, Ipsen

The following SPC members reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Larry Fox, MD; Michael S Irwig, MD; Connie B Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.00 AMA PRA Category 1 Credits
  • 2.00 CME Certificate of Participation